Navigation Links
Ability to track stem cells in tumors could advance cancer treatments
Date:6/16/2008

NEW ORLEANS, La.Using noninvasive molecular imaging technology, a method has been developed to track the location and activity of mesenchymal stem cells (MSCs) in the tumors of living organisms, according to researchers at SNM's 55th Annual Meeting. This ability could lead to major advances in the use of stem cell therapies to treat cancer.

"Stem cell cancer therapies are still in the early stages of development, but they offer great promise in delivering personalized medicine that will fight disease at the cellular level," said Hui Wang, a postdoctoral fellow from Prof. Xiaoyuan (Shawn) Chen's group of the Molecular Imaging Program at Stanford (MIPS), Department of Radiology at Stanford University, Stanford, Calif., and lead researcher of the study, Trafficking the Fate of Mesenchymal Stem Cells In Vivo. "Our results indicate that molecular imaging can play a critical role in understanding and improving the process of how stem cells migrate to cancer cells. Eventually, this technique could also be used to determine if gene-modified stem cells are effective in fighting cancer."

MSCs are adult stem cells that have the ability to transform into many different types of cells, such as bone, fat or cartilage. Many scientists believe that stem cells show great promise in treating different types of diseasesand a few stem cell therapies are already used to fight some types of cancer. Leukemia patients who haven't responded to chemotherapy, for example, may receive bone marrow transplants, through which stem cells of a healthy bone marrow donor are injected into the patient's blood stream. If the transplant is successful, the stem cells will migrate to the patient's bone marrow and begin producing healthy cells that will replace the cancer cells. For other types of cancer, researchers are experimenting with modifying stem cells that could be engineered to deliver chemotherapy more precisely to specific tumor sites.

For these types of treatments to be successful, the ability to track what happens to stem cells after they are injected into a living organism is essential. Currently, three different tracking techniques are used: radiolabeling, which consists of using a radioactive substance to tag the cells; magnetic labeling, or using magnetic nanoparticles to tag cells for magnetic resonance imaging; and reporter-gene tracking, which involves engineering genes that can adhere to cells and be tracked with molecular imaging technologies. Of these, reporter gene techniques are highly sensitive and able to monitor cell migration, survival and proliferation over time in living organisms.

In their research, Wang and her team isolated stem cells from adult mice and engineered a reporter gene that would be both luminescent and green under a special microscope. Two tumor models were also tagged with reporter genes that were luminescent and red. The tumor cells were injected into live mice either intravenously or under the skin, followed days later by injection of the engineered stem cells.

The study produced solid evidence that the injected stem cells migrate to the tumors and don't begin to differentiate into other types of cells until they are at the tumor sites. In some of the mice, the breast cancer cells had begun to spread to the lungs. Researchers found that the injected stem cells also migrated to the lung cancer tumors. In addition, the stem cells that migrated to lung tumors differentiated into bone cells, while the stem cells that migrated to breast cancer tumors differentiated into fat cells. The results indicate that stem cells can migrate both to breast cancer cells and their lung metastasis. In addition, the MSCs differentiate into distinctly different cells. "The next logical step of this study is to incorporate therapeutic genes into MSCs and use multimodality molecular imaging techniques to follow the distribution, homing, survival, proliferation and cell/gene therapy efficacy of the MSC platform," said Wang.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Therap Services Announces Release 7.3 for the Developmental Disability Community
2. The HealthCentral Network Acquires MedTrackAlert, Extending its Ability to Reach Highly Engaged Online Health Consumers
3. Four Out of Five Disability Income Insurance Claimants are Satisfied With Their Policy
4. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
5. Unilens Vision Announces New Policies Aimed at Increasing Eye Care Professionals Profitability
6. Treatment improves walking ability of Parkinsons patients
7. New data show patients using avonex reported less sick leave and short-term disability costs
8. Long-term bouts with hay fever worsen ability to breathe through your nose
9. Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability
10. Vaseline(R) Cocoa Butter Campaign Uncovers Skins Ability to Speak Volumes
11. Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... Experimentation involving human stem cells (HSCs) ... to its potential for revolutionizing human disease treatment. There are multiple HSC platforms ... cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but what ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... TopConsumerReviews.com recently ... Mobility Scooters . , Mobility Scooters give freedom to people who need help ... Still others may be facing a long period of rehabilitation after an illness or ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: